Reemergence of Mycoplasma pneumoniae disease: Pathogenesis and new approaches

Tahmasebi, Hamed; Babaeizad, Ali; Mohammadlou, Maryam; Alibabaei, Farnaz; Banihashemian, Seyedeh Zahra; Eslami, Majid

doi:10.1016/j.micpath.2024.106944

Microbial Pathogenesis

2024

DOI: 10.1016/j.micpath.2024.106944

|View full text |Cite

Reemergence of Mycoplasma pneumoniae disease: Pathogenesis and new approaches

Hamed Tahmasebi,

Ali Babaeizad,

Maryam Mohammadlou

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

The role of macrolides in severe community-acquired pneumonia and the potential impact of macrolide-resistant Mycoplamsa pneumoniae

Antonakos,

Giamarellos-Bourboulis,

Niederman

2024

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Define the utility of adjunctive macrolide therapy in patients with more severe forms of community-acquired pneumonia (CAP). Recent findings Guidelines recommend adjunctive macrolide therapy as an option for patients with CAP, admitted to the hospital. A large data set collected both retrospectively and prospectively, including several recent randomized controlled trials (RCTs) have shown that adjunctive macrolide therapy can reduce mortality and improve outcomes in patients with severe CAP, more effectively than other alternative therapies. This effect appears to be most evident in those with severe illness and appears to be independent of direct antimicrobial effects and may be a result of the immunomodulatory properties of macrolides. A recent RCT, the ACCESS study, showed a clinical benefit of macrolides in severe CAP patients, but this may have been the result of a reversal of infection-related immunoparalysis. Macrolides appear to be valuable for patients with more severe CAP, but their therapeutic value is being challenged by the recent emergence of macrolide-resistant Mycoplasma pneumoniae; however, the optimal therapy for this pathogen still needs to be defined. Summary New evidence has further advanced the role of macrolides as preferred adjunctive therapy for patients with severe CAP.

show abstract

The role of macrolides in severe community-acquired pneumonia and the potential impact of macrolide-resistant Mycoplamsa pneumoniae

Antonakos,

Giamarellos-Bourboulis,

Niederman

2024

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Reemergence of Mycoplasma pneumoniae disease: Pathogenesis and new approaches

Cited by 1 publication

References 47 publications

The role of macrolides in severe community-acquired pneumonia and the potential impact of macrolide-resistant Mycoplamsa pneumoniae

The role of macrolides in severe community-acquired pneumonia and the potential impact of macrolide-resistant Mycoplamsa pneumoniae

Contact Info

Product

Resources

About